New biomarker paves the way for a clinical trial for neurodegeneration in Langerhans cell histiocytosis | Zendy

Shioda Yoko | Zendy; Sakamoto Kenichi | Zendy; Morimoto Akira | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

New biomarker paves the way for a clinical trial for neurodegeneration in Langerhans cell histiocytosis

Author(s) -

Shioda Yoko,

Sakamoto Kenichi,

Morimoto Akira

Publication year - 2022

Publication title -

british journal of haematology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.907

H-Index - 186

eISSN - 1365-2141

pISSN - 0007-1048

DOI - 10.1111/bjh.18308

Subject(s) - neurodegeneration , biomarker , langerhans cell histiocytosis , medicine , clinical trial , histiocytosis , disease , biology , genetics

Summary Neurodegeneration in Langerhans cell histiocytosis (ND‐LCH) is a major clinical issue requiring urgent resolution. Sveijer et al. showed that plasma neurofilament light protein is a promising biomarker for screening patients with ND‐LCH and determining the therapeutic effect of a mitogen‐activated protein kinase inhibitor. Therefore, this can be a powerful tool for conducting clinical trials for ND‐LCH. Commentary on: Sveijer M, von Bahr Greenwood T, Jädersten M, Kvedaraite E, Zetterberg H, Blennow K, et al. Screening for neurodegeneration in Langerhans cell histiocytosis with neurofilament light in plasma. Br J Haematol. 2022;198:722–729

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research